BOLT
Bolt Biotherapeutics, Inc.Company Information
- Company Name
- Bolt Biotherapeutics, Inc.
- CIK
- CIK0001641281
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BOLT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BOLT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-05
- Last sale
- 2026-09-18
- Shares purchased (TTM)
- 1,396
- Shares sold (TTM)
- 20,059
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 596,819
- Shares outstanding
- 1,690,529
- Ownership
- 35.30%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -2.01%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 12 | 12 | 18 | 10 | 8 | 7 | 9 | 6 | 4 | 11 | 9 | ||||||
| Short Term Investments | 5 | 11 | 16 | 14 | 25 | 30 | 40 | 44 | 67 | 87 | 91 | 111 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | ||||||
| Assets Current | 21 | 26 | 30 | 36 | 38 | 43 | 51 | 57 | 77 | 95 | 106 | 125 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 5 | 5 | ||||||
| Operating Lease Right Of Use Asset | 17 | 19 | 19 | 20 | 21 | 21 | 22 | 17 | 18 | 18 | 19 | 20 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Long Term Investments | 1 | 1 | 4 | 7 | 14 | 19 | 23 | 31 | 24 | 21 | 26 | 22 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | ||||||
| Assets | 40 | 48 | 57 | 65 | 75 | 86 | 100 | 109 | 124 | 143 | 160 | 175 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 3 | 2 | 3 | 4 | ||||||
| Deferred Revenue Current | 1 | 1 | 0 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 8 | 7 | 8 | 10 | 12 | 14 | 16 | 18 | 18 | 17 | 20 | 19 | ||||||
| Operating Lease Liability Noncurrent | 19 | 19 | 20 | 21 | 22 | 22 | 23 | 15 | 16 | 17 | 17 | 18 | ||||||
| Deferred Revenue Noncurrent | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 9 | 10 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 28 | 28 | 30 | 33 | 37 | 39 | 42 | 37 | 38 | 39 | 47 | 47 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 488 | 488 | 487 | 486 | 486 | 485 | 485 | 483 | 482 | 479 | 477 | 475 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -476 | -468 | -461 | -454 | -447 | -438 | -427 | -411 | -396 | -375 | -364 | -346 | ||||||
| Stockholders Equity | 13 | 20 | 27 | 32 | 39 | 47 | 57 | 72 | 86 | 104 | 113 | 128 | ||||||
| Liabilities And Stockholders Equity | 40 | 48 | 57 | 65 | 75 | 86 | 100 | 109 | 124 | 143 | 160 | 175 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBolt Biotherapeutics, Inc. (BOLT) — SEC Financial Statements & Analysis
Bolt Biotherapeutics, Inc. (BOLT) is a pharmaceutical preparations company, incorporated in DE. Bolt Biotherapeutics, Inc. trades on Nasdaq as: BOLT. Bolt Biotherapeutics, Inc. (BOLT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Bolt Biotherapeutics, Inc. carries a market cap of $6.51M, a P/E ratio of -0.23x, a P/B ratio of 0.51x, a P/S ratio of 1.38x, an enterprise value of $-6.35M, and an EV/EBITDA multiple of 0.21x. On profitability, it posts an operating margin of -654.53%, a net margin of -611.47%, a Return on Equity (ROE) of -111.65%, a Return on Assets (ROA) of -49.62%, and a Return on Invested Capital (ROIC) of -145.85%. Per share, it reports EPS of $-17.00, diluted EPS of $-17.00, free cash flow per share of $-18.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.79% year-over-year, net income growth of -43.33% year-over-year, and EPS growth of -35.72% year-over-year. On the balance sheet, it maintains a current ratio of 2.61x, a quick ratio of 2.26x, working capital of $12.70M, a debt-to-equity ratio of 2.19x, a debt ratio of 0.69, free cash flow of $-31.54M (TTM), and net debt of $-12.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.51M
- P/E TTM
- -0.23x
- EPS TTM
- $-17.00
- P/B TTM
- 0.51x
- ROE TTM
- -111.65%
- ROA TTM
- -49.62%
- Debt To Equity
- 2.19x
- Free Cash Flow TTM
- $-31.54M
- Net Revenue TTM Growth 1Y
- 12.79%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Bolt Biotherapeutics, Inc. in?
Bolt Biotherapeutics, Inc. (BOLT) operates in the Pharmaceutical Preparations industry.
What exchange does BOLT trade on?
Bolt Biotherapeutics, Inc. (BOLT) trades on the Nasdaq.
Where is Bolt Biotherapeutics, Inc. incorporated?
Bolt Biotherapeutics, Inc. is incorporated in DE.
When was Bolt Biotherapeutics, Inc. (BOLT)'s most recent SEC filing?
Bolt Biotherapeutics, Inc. (BOLT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is BOLT's market cap?
Bolt Biotherapeutics, Inc. (BOLT) has a market capitalization of $6.51M as of 2026-06-30.
What is BOLT's EPS (earnings per share)?
Bolt Biotherapeutics, Inc. (BOLT)'s trailing twelve month EPS is $-17.00 as of 2026-06-30.
What is BOLT's ROE (return on equity)?
Bolt Biotherapeutics, Inc. (BOLT)'s trailing twelve month Return on Equity (ROE) is -111.65% as of 2026-06-30.
What is BOLT's ROA (return on assets)?
Bolt Biotherapeutics, Inc. (BOLT)'s trailing twelve month Return on Assets (ROA) is -49.62% as of 2026-06-30.
What is BOLT's ROIC (return on invested capital)?
Bolt Biotherapeutics, Inc. (BOLT)'s trailing twelve month Return on Invested Capital (ROIC) is -145.85% as of 2026-03-31.
What is BOLT's EV/EBITDA?
Bolt Biotherapeutics, Inc. (BOLT)'s trailing twelve month EV/EBITDA is 0.21x as of 2026-06-30.